Drugs / Rilapladib
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT02130661 | Oct 2017 → Jan 2018 | Alzheimer disease | GlaxoSmithKline | Withdrawn | No outcome recorded |
| Phase 1 | NCT00387257 | Oct 2006 → Apr 2007 | atherosclerosis | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT01750827 | Sep → Nov 2004 | atherosclerosis | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 21 trial · 1 missed | ||||||
| Phase 2 | NCT01428453 | Oct 2011 → Feb 2013 | Alzheimer disease | GlaxoSmithKline | Completed | Missed primary |
| Comparator or background therapy2 trials | ||||||
| Phase 1 | NCT01745458 Comparator | Jul → Dec 2005 | atherosclerosis | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT00695305 Comparator | Nov 2008 → May 2010 | atherosclerosis | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Rilapladib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02130661 ↗ |
| Known as | SB-659032 | “The lipoprotein-associated phospholipase A2 inhibitor (Lp-PLA2), rilapladib (SB659032), is being evaluated as a potential treatment to slow the progression of Alzheimer's disease (AD).” PMID 29854933 ↗ Jun 2015 |
| Action | Inhibit | “LDL-associated phospholipase A2 inhibitor” CHEMBL2104981 ↗1“rilapladib (selective Lp-PLA2 inhibitor)” PMID 24475026 ↗ Jan 2014 |
| Modality | Small molecule | — CHEMBL2104981 ↗ |
| Route | Oral | “250 mg oral rilapladib or placebo once daily for 14 days” PMID 24475026 ↗ Jan 2014 |
| Target | PLA2G7 | “LDL-associated phospholipase A2 inhibitor” CHEMBL2104981 ↗ |